A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Auranofin (RIDAURA)

First FDA approval2016-12-15
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$1.4M in CY2024 Part D spend940 claims · 174 beneficiaries · 329 plans surveyed

Lowest NADAC
$24.85/unit
1 NDCs benchmarked, lowest of all strengths.
Average NADAC
$24.85
Across all dosage forms in distribution.
Highest NADAC
$24.85
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Auranofin used for?

Auranofin is a this drug class medication tracked in Medicare Part D.

Is there a generic for Auranofin?

No. Auranofin is brand-only with no generic equivalents currently in market.

How much does my plan pay for Auranofin?

Across 329 Part D plans, Auranofin averages $24.85/unit (NADAC). Lowest available: $24.85/unit. Highest in distribution: $24.85/unit.

Is Auranofin on the FDA shortage list?

No. Auranofin is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (1 approvals on file) · NADAC unit costs: CMS NADAC weekly file (1 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.